SI1767221T1 - Priprava in uporaba dvovalentnega cepiva proti odvisnosti od morfina-heroina - Google Patents

Priprava in uporaba dvovalentnega cepiva proti odvisnosti od morfina-heroina

Info

Publication number
SI1767221T1
SI1767221T1 SI200531802T SI200531802T SI1767221T1 SI 1767221 T1 SI1767221 T1 SI 1767221T1 SI 200531802 T SI200531802 T SI 200531802T SI 200531802 T SI200531802 T SI 200531802T SI 1767221 T1 SI1767221 T1 SI 1767221T1
Authority
SI
Slovenia
Prior art keywords
heroine
addiction
preparation
vaccine against
bivalent vaccine
Prior art date
Application number
SI200531802T
Other languages
English (en)
Inventor
Palma Benito Anton
Gelman Philippe Leff
Original Assignee
Instituto Nacional De Psiquiatria Ramon De La Fuente Muniz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto Nacional De Psiquiatria Ramon De La Fuente Muniz filed Critical Instituto Nacional De Psiquiatria Ramon De La Fuente Muniz
Publication of SI1767221T1 publication Critical patent/SI1767221T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/141111—Diverse hetero atoms in same or different rings [e.g., alkaloids, opiates, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SI200531802T 2004-07-07 2005-07-05 Priprava in uporaba dvovalentnega cepiva proti odvisnosti od morfina-heroina SI1767221T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
MXPA04006617A MXPA04006617A (es) 2004-07-07 2004-07-07 Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina.
PCT/MX2005/000049 WO2006004390A2 (es) 2004-07-07 2005-07-05 Proceso para la preparación y uso de una vacuna bivalente contra la adicción a la morfina-heroína
EP05761917.3A EP1767221B1 (en) 2004-07-07 2005-07-05 Preparation and use of a bivalent vaccine against morphine-heroine addiction

Publications (1)

Publication Number Publication Date
SI1767221T1 true SI1767221T1 (sl) 2014-01-31

Family

ID=35431510

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531802T SI1767221T1 (sl) 2004-07-07 2005-07-05 Priprava in uporaba dvovalentnega cepiva proti odvisnosti od morfina-heroina

Country Status (15)

Country Link
US (4) US8008457B2 (sl)
EP (1) EP1767221B1 (sl)
AR (1) AR049962A1 (sl)
BR (1) BRPI0513024A (sl)
CA (1) CA2573042C (sl)
CU (1) CU23917B1 (sl)
CY (1) CY1114673T1 (sl)
DK (1) DK1767221T3 (sl)
ES (1) ES2435769T3 (sl)
MX (1) MXPA04006617A (sl)
PE (1) PE20060377A1 (sl)
PL (1) PL1767221T3 (sl)
PT (1) PT1767221E (sl)
SI (1) SI1767221T1 (sl)
WO (1) WO2006004390A2 (sl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04006617A (es) 2004-07-07 2006-01-12 Inst Nac De Psiquiatria Ramon Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina.
US8170546B2 (en) 2006-03-22 2012-05-01 Broadcom Corporation Client device characterization of other client device transmissions and reporting of signal qualities to access point(s)
EP1982729A1 (en) * 2007-04-20 2008-10-22 Cytos Biotechnology AG Vaccination Regimen for B-Cell Vaccines
WO2011041483A2 (en) * 2009-09-30 2011-04-07 Toxcure, Inc. Use of botulinum neurotoxin to treat substance addictions
CN102002049B (zh) * 2010-10-12 2013-01-02 北京大学 一种抗原及其制备方法与应用
CN102539764A (zh) * 2010-12-27 2012-07-04 北京库尔科技有限公司 盐酸哌替啶检测试剂盒及其制备方法
EP2717057A1 (en) * 2012-10-04 2014-04-09 Cisbio Bioassays Morphine-6-glucuronide derivatives, immunogens and immunoassay
RU2526807C2 (ru) * 2012-11-28 2014-08-27 Общество с ограниченной ответственностью "ДИАМЕДИКА" ООО "ДИАМЕДИКА" Синтетический иммуноген для защиты от токсического действия наркотических и психоактивных веществ
EP2970320B1 (en) 2013-03-15 2020-10-28 Johnson Matthey Public Limited Company Morphine sulfate methanolic solvate, processes for making same and related compositions and methods for treating pain
US10262505B1 (en) * 2013-12-03 2019-04-16 Ca, Inc. Anti-skimming solution
WO2017127390A1 (en) 2016-01-21 2017-07-27 The Scripps Research Institute Synthetic opioid vaccine
WO2019094528A1 (en) 2017-11-09 2019-05-16 The Scripps Research Institute An improved heroin vaccine
WO2020012245A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Thienothiophene-naltrexone prodrugs for long-acting injectable compositions
WO2020012248A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Novel naphthylenyl compounds for long-acting injectable compositions and related methods
WO2020094634A1 (en) 2018-11-05 2020-05-14 Alkermes Pharma Ireland Limited Thiophene prodrugs of naltroxene for long-acting injectable compositions and related methods
RU2703494C1 (ru) * 2018-11-12 2019-10-18 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Моноклональное антитело 6g1 к производным морфина

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH678394A5 (sl) 1990-08-22 1991-09-13 Cerny Erich H
US6210677B1 (en) * 1993-01-29 2001-04-03 Robert C. Bohannon Method to reduce the physiologic effects of drugs on mammals
US5876727A (en) * 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
DE69637089T2 (de) 1995-03-31 2008-01-17 Xenova Research Ltd., Slough Hapten-Träger-Konjugate zur Anwendung in der Drogen-Missbrauchs-Therapie
US20020032316A1 (en) * 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
CN1069544C (zh) 1998-04-24 2001-08-15 昆明市生物技术工程研究中心 人用阿片类毒品戒毒疫苗
AU2004215125B2 (en) * 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
MXPA04006617A (es) 2004-07-07 2006-01-12 Inst Nac De Psiquiatria Ramon Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina.

Also Published As

Publication number Publication date
CA2573042C (en) 2013-01-15
US20150064212A1 (en) 2015-03-05
US20080241183A1 (en) 2008-10-02
EP1767221B1 (en) 2013-08-21
BRPI0513024A (pt) 2008-04-22
EP1767221A2 (en) 2007-03-28
US20130236478A1 (en) 2013-09-12
US20110318381A1 (en) 2011-12-29
US8357375B2 (en) 2013-01-22
DK1767221T3 (da) 2013-11-25
PL1767221T3 (pl) 2014-02-28
CY1114673T1 (el) 2016-10-05
WO2006004390A2 (es) 2006-01-12
PE20060377A1 (es) 2006-05-05
PT1767221E (pt) 2013-11-27
MXPA04006617A (es) 2006-01-12
US8008457B2 (en) 2011-08-30
CU23917B1 (es) 2013-07-31
CA2573042A1 (en) 2006-01-12
ES2435769T3 (es) 2013-12-23
WO2006004390A3 (es) 2006-09-21
CU20070002A7 (es) 2009-09-08
AR049962A1 (es) 2006-09-20
US8916170B2 (en) 2014-12-23

Similar Documents

Publication Publication Date Title
SI1767221T1 (sl) Priprava in uporaba dvovalentnega cepiva proti odvisnosti od morfina-heroina
EP1804831A4 (en) VACCINES BASED ON LLO AND LISTERIA
IL213843A0 (en) 4-aminotetracyclines and methods of use thereof
IL183929A0 (en) Use of inerferon - ?? in the preparation of a medicament
EP1827391A4 (en) DOSAGE FORMS AND METHODS OF USE THEREOF
PL1722710T3 (pl) Sposób oraz element znacznikowy do ustalania położenia implantu dentystycznego
EP1789109A4 (en) DIALYSIS IMPLANT AND METHODS OF USE
HK1103370A1 (en) Respiratory devices and methods of use
ZA200700705B (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
HK1117082A1 (en) A medicinal fatheadtree extract and preparation and use thereof
EP1778210A4 (en) CONJUGATES OF FATTY ACID AND AMINO ACIDS AND METHODS OF USE
EP2033653A4 (en) CHINESE MEDICINE COMPOSITION AND PREPARATION METHOD AND ITS USE
IL177047A0 (en) Oxazole derivatives, preparation and therapeutic use thereof
IL181733A0 (en) Vaccines comprising plasmodium antigens
PL1773796T3 (pl) Oksopiperydynowe pochodne, ich wytwarzanie i zastosowanie terapeutyczne
ZA200900203B (en) Adjuvants and methods of use
EP1773386A4 (en) VACCINE COMPOSITIONS AND CORRESPONDING METHODS
EP1721619A4 (en) PREPARATION FOR FLEXIBLE CAPSULE
EP1814393A4 (en) TOLEROGENIC VACCINE AND METHOD THEREOF
IL180797A0 (en) Amino-tropane derivatives, preparation thereof and therapeutic use thereof
EP1740120A4 (en) LONG-TERM FORMULATIONS OF NALTREXONE AND METHOD OF USE
ZA200701675B (en) Multivalent meningococcal derivatized polysaccharideprotein conjugates and vaccine
IL181819A (en) Use of Benzo-compound compounds for the preparation of pharmaceuticals and the uses of these @ compounds
IL179331A0 (en) Preparation of levalbuterol hydrochloride
EP1735338A4 (en) ANTHROX ANTIGENS AND METHODS OF USE